Birchview Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Birchview Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-57,000	Closed	-$1.15M	–	77
2026 Q1	$1.15M	Hold	57,000	–	–	0.65%	38
2025 Q4	$921K	Sell	57,000 -10,000	-15%	-$132K	0.54%	42
2025 Q3	$816K	Hold	67,000	–	–	0.62%	41
2025 Q2	$757K	Sell	67,000 -2	-0%	-$24	0.75%	30
2025 Q1	$773K	Buy	67,002 +2	+0%	+$20	0.67%	25
2024 Q4	$567K	Sell	67,000 -15,000	-18%	-$155K	0.46%	29
2024 Q3	$950K	Buy	82,000 +36,000	+78%	+$453K	0.82%	24
2024 Q2	$542K	Hold	46,000	–	–	0.5%	29
2024 Q1	$546K	Buy	46,000 +6,000	+15%	+$80K	0.44%	34
2023 Q4	$490K	Hold	40,000	–	–	0.38%	34
2023 Q3	$385K	Hold	40,000	–	–	0.33%	35
2023 Q2	$360K	Hold	40,000	–	–	0.27%	42
2023 Q1	$314K	Hold	40,000	–	–	0.25%	42
2022 Q4	$270K	Hold	40,000	–	–	0.19%	44
2022 Q3	$580K	Hold	40,000	–	–	0.41%	36
2022 Q2	$394K	Hold	40,000	–	–	0.29%	43
2022 Q1	$590K	Hold	40,000	–	–	0.42%	38
2021 Q4	$529K	Hold	40,000	–	–	0.34%	42
2021 Q3	$698K	Hold	40,000	–	–	0.48%	34
2021 Q2	$958K	Hold	40,000	–	–	0.57%	33
2021 Q1	$1.03M	Buy	40,000 +10,000	+33%	+$263K	0.61%	28
2020 Q4	$570K	Hold	30,000	–	–	0.33%	38
2020 Q3	$378K	Hold	30,000	–	–	0.25%	38
2020 Q2	$363K	Hold	30,000	–	–	0.22%	43
2020 Q1	$230K	Hold	30,000	–	–	0.2%	40
2019 Q4	$534K	Hold	30,000	–	–	0.39%	34
2019 Q3	$348K	Buy	+30,000	New	+$485K	0.23%	35

Other funds holding KALV

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Birchview Capital's KALV Position: Q2 2026 in Review

Birchview Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 57,000 shares — an estimated $1.15M sold.

Birchview Capital first reported a position in KALV in Q3 2019 and held it in 27 quarters. The position peaked at $1.15M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Birchview Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Birchview Capital sold 57,000 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.15M.
Birchview Capital first reported a position in KalVista Pharmaceuticals in Q3 2019 and held it in 27 quarters.
Birchview Capital's KalVista Pharmaceuticals position peaked at $1.15M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.